Clinical Policy: Vedolizumab (Entyvio)
Reference Number: CP.PHAR.265
Effective Date: 07.16
Last Review Date: 05.20
Line of Business: Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Vedolizumab (Entyvio®) is an integrin receptor antagonist.

FDA Approved Indication(s)
Entyvio is indicated for the treatment of:
- Adult ulcerative colitis
  - Adult patients with moderately to severely active UC who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids:
    - Inducing and maintaining clinical response,
    - Inducing and maintaining clinical remission,
    - Improving the endoscopic appearance of the mucosa, and
    - Achieving corticosteroid-free remission.
- Adult Crohn’s disease
  - Adult patients with moderately to severely active CD who have had an inadequate response with, lost response to, or were intolerant to a TNF blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids:
    - Achieving clinical response,
    - Achieving clinical remission, and
    - Achieving corticosteroid-free remission.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Entyvio is medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Ulcerative Colitis (must meet all):
      1. Diagnosis of UC;
      2. Prescribed by or in consultation with a gastroenterologist;
      3. Age ≥ 18 years;
      4. Documentation of a Mayo Score ≥ 6 (see Appendix F);
      5. Failure of an 8-week trial of systemic corticosteroids, unless contraindicated or
CLINICAL POLICY
Vedolizumab

clinically significant adverse effects are experienced;
6. Failure of a ≥ 3 consecutive month trial of Humira or Simponi®, unless contraindicated or clinically significant adverse effects are experienced;

*Prior authorization is required for Humira and Simponi
7. Dose does not exceed 300 mg at weeks 0, 2, and 6, followed by maintenance dose of 300 mg every 8 weeks.

Approval duration: 6 months

B. Crohn’s Disease (must meet all):
1. Diagnosis of CD;
2. Prescribed by or in consultation with a gastroenterologist;
3. Age ≥ 18 years;
4. Member meets one of the following (a or b):
   a. Failure of a ≥ 3 consecutive month trial of at least ONE immunomodulator (e.g., azathioprine, 6-MP, methotrexate [MTX]) at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;
   b. Medical justification supports inability to use immunomodulators (see Appendix E);
5. Failure of a ≥ 3 consecutive month trial of adalimumab (Humira is preferred) AND one other TNF blocker (e.g., infliximab [Inflectra and Renflexis are preferred], Cimzia®), unless contraindicated or clinically significant adverse effects are experienced;

*Prior authorization is required for adalimumab and all TNF blockers
6. Dose does not exceed 300 mg at weeks 0, 2, and 6, followed by maintenance dose of 300 mg every 8 weeks.

Approval duration: 6 months

C. Other diagnoses/indications
1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.PMN.53 for Medicaid.

II. Continued Therapy
A. All Indications in Section I (must meet all):
1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Member is responding positively to therapy;
3. If request is for a dose increase, new dose does not exceed 300 mg every 8 weeks.

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):
1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.
Approval duration: Duration of request or 6 months (whichever is less); or
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:
A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key
6-MP: 6-mercaptopurine
CD: Crohn’s disease
FDA: Food and Drug Administration
GI: gastrointestinal
MTX: methotrexate
TNF: tumor necrosis factor
UC: ulcerative colitis

Appendix B: Therapeutic Alternatives
This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td>azathioprine (Azasan®, Imuran®)</td>
<td>CD* 1.5 – 2 mg/kg/day PO</td>
<td>2.5 mg/kg/day</td>
</tr>
<tr>
<td>corticosteroids</td>
<td>CD* prednisone 40 mg PO QD for 2 weeks or IV 50 – 100 mg Q6H for 1 week budesonide (Entocort EC®) 6 – 9 mg PO QD</td>
<td>N/A</td>
</tr>
<tr>
<td>6-mercaptopurine (Purixan®)</td>
<td>CD* 50 mg PO QD or 1 – 2 mg/kg/day PO</td>
<td>2 mg/kg/day</td>
</tr>
<tr>
<td>mesalamine (Pentasa®)</td>
<td>CD 1,000 mg PO QID</td>
<td>4 g/day</td>
</tr>
<tr>
<td>Cimzia® (certolizumab)</td>
<td>CD Initial dose: 400 mg SC at 0, 2, and 4 weeks</td>
<td>400 mg every 4 weeks</td>
</tr>
<tr>
<td>Drug Name</td>
<td>Dosing Regimen</td>
<td>Dose Limit/Maximum</td>
</tr>
<tr>
<td>---------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td><strong>Vedolizumab</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maintenance dose:</td>
<td>400 mg SC every 4 weeks</td>
<td></td>
</tr>
<tr>
<td>Humira® (adalimumab)</td>
<td><strong>CD, UC</strong>&lt;br&gt;Initial dose: 160 mg SC on Day 1, then 80 mg SC on Day 15</td>
<td>40 mg every other week</td>
</tr>
<tr>
<td></td>
<td>Maintenance dose: 40 mg SC every other week starting on Day 29</td>
<td></td>
</tr>
<tr>
<td>Renflexis®, Inflectra®</td>
<td><strong>CD</strong>&lt;br&gt;Initial dose: 5 mg/kg IV at weeks 0, 2 and 6&lt;br&gt;Maintenance dose: 5 mg/kg IV every 8 weeks.</td>
<td>CD: 10 mg/kg every 8 weeks&lt;br&gt;UC: 5 mg/kg every 8 weeks</td>
</tr>
<tr>
<td></td>
<td>Some adult patients who initially respond to treatment may benefit from increasing the dose to 10 mg/kg if they later lose their response</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>UC</strong>&lt;br&gt;Initial dose: 5 mg/kg IV at weeks 0, 2 and 6&lt;br&gt;Maintenance dose: 5 mg/kg IV every 8 weeks.</td>
<td></td>
</tr>
</tbody>
</table>

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

*Off-label

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): patients who have had a known serious or severe hypersensitivity reaction to Entyvio or any of its excipients
- Boxed warning(s): none reported

Appendix D: General Information

- Definition of failure of MTX or DMARDs
  - Child-bearing age is not considered a contraindication for use of MTX. Each drug has risks in pregnancy. An educated patient and family planning would allow use of MTX in patients who have no intention of immediate pregnancy.
  - Social use of alcohol is not considered a contraindication for use of MTX. MTX may only be contraindicated if patients choose to drink over 14 units of alcohol per week. However, excessive alcohol drinking can lead to worsening of the condition, so
patients who are serious about clinical response to therapy should refrain from excessive alcohol consumption.

Appendix E: Medical Justification

- The following may be considered for medical justification supporting inability to use an immunomodulator for Crohn’s disease:
  - Inability to induce short-term symptomatic remission with a 3-month trial of systemic glucocorticoids
  - High-risk factors for intestinal complications may include:
    - Initial extensive ileal, ileocolonic, or proximal GI involvement
    - Initial extensive perianal/severe rectal disease
    - Fistulizing disease (e.g., perianal, enterocutaneous, and rectovaginal fistulas)
    - Deep ulcerations
    - Penetrating, stricturing or stenosis disease and/or phenotype
    - Intestinal obstruction or abscess

Appendix F: Mayo Score

- Mayo Score: evaluates ulcerative colitis stage, based on four parameters: stool frequency, rectal bleeding, endoscopic evaluation and Physician’s global assessment. Each parameter of the score ranges from zero (normal or inactive disease) to 3 (severe activity) with an overall score of 12.

<table>
<thead>
<tr>
<th>Score</th>
<th>Decoding</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 – 2</td>
<td>Remission</td>
</tr>
<tr>
<td>3 – 5</td>
<td>Mild activity</td>
</tr>
<tr>
<td>6 – 10</td>
<td>Moderate activity</td>
</tr>
<tr>
<td>&gt;10</td>
<td>Severe activity</td>
</tr>
</tbody>
</table>

- The following may be considered for medical justification supporting inability to use an immunomodulator for ulcerative colitis:
  - Documentation of Mayo Score 6 – 12 indicative of moderate to severe ulcerative colitis.

V. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>UC, CD</td>
<td>Initial dose: 300 mg IV at weeks 0, 2, and 6</td>
<td>300 mg every 8 weeks</td>
</tr>
<tr>
<td></td>
<td>Maintenance dose: 300 mg IV every 8 weeks</td>
<td></td>
</tr>
</tbody>
</table>

VI. Product Availability

Single-use vial: 300 mg/20 mL

VII. References

2. Lichtenstein GR, Loftus Jr. EV, Isaacs KI, Regueiro MD, Gerson LB, and Sands BE.


Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

<table>
<thead>
<tr>
<th>HCPSC Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J3380</td>
<td>Injection, vedolizumab, 1 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Reviews, Revisions, and Approvals</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy split from CP.PHAR.87.IBD Treatment_4_.</td>
<td>06.16</td>
<td>07.16</td>
</tr>
<tr>
<td>CD/UC: removed criteria related to concomitant use with other biologics, and concurrent administration of live; added dosing; added requirement for trial and failure of PDL Humira as one of the two required TNF inhibitors, unless contraindicated. CD: added poor prognostic indicators; modified criteria requiring failure of immunomodulator, corticosteroids or aminosalicylate to failure of “corticosteroid, with or without immunomodulator” per 2014 AGA Clinical decision tool. Re-auth: added criteria related to dosing per PI and reasons to discontinue. Modified approval duration to 6 months initial and 12 months for renewal.</td>
<td>11.16</td>
<td></td>
</tr>
<tr>
<td>Removed trial and failure of corticosteroid as an option for moderate to severe CD, per 2014 AGA Clinical decision tool- corticosteroids are appropriate for low-risk patients. UC: removed option of trial of aminosalicylates per 2015 AGA Clinical Care Pathway.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.17</td>
<td>07.17</td>
</tr>
<tr>
<td>08.17</td>
<td></td>
</tr>
<tr>
<td>02.27.18</td>
<td>05.18</td>
</tr>
<tr>
<td>08.28.18</td>
<td>11.18</td>
</tr>
<tr>
<td>02.26.19</td>
<td>05.19</td>
</tr>
<tr>
<td>02.28.20</td>
<td>05.20</td>
</tr>
</tbody>
</table>

#### Converted to new template. UC: removed Cimzia as example of second TNF for redirection as Cimzia is not indicated for UC; change required trials from immunomodulator to specifically thiopurines based on AGA and ACG guidelines and removed MTX as example of acceptable trial. Clarified immunomodulator redirection for maintenance requests for all indications. CD: modified poor prognostic indicator list to match AGA guidelines. Safety criteria revised according to the safety guidance discussed at CPAC and endorsed by Centene Medical Affairs.

#### CD: Reclassified “failure of an immunomodulator…” as one of the options to meet criteria point 1 (along with other poor prognostic indicators), instead of as an alternative to failing Humira and another TNF inhibitor in criteria point 2.

#### 2Q 2018 annual review: modified gastroenterologist specialty requirement to gastrointestinal specialist; modified trial and failure of all agents for all conditions to have duration of at least 3 consecutive months; added aminosalicylate as an option for trial and failure for UC; specified brand names for preferred trial and failure agents in all conditions; removed specific diagnosis requirements for CD; references reviewed and updated.

#### 4Q 2018 annual review: modified prescriber specialist from GI specialist to gastroenterologist for CD and UC; added trial and failure of immunosuppressants, or medical necessity for use of biologics in CD; references reviewed and updated.

#### 2Q 2019 annual review: no significant changes; added HIM-Medical Benefit; references reviewed and updated.

#### 2Q 2020 annual review; removed HIM-Medical Benefit (see HIM.PA.SP60); for UC, revised redirection from AZA, 6-MP, and ASA to systemic corticosteroids, revised redirection from Humira and another TNFi to Humira or Simponi, and added Mayo score requirement of at least 6; references reviewed and updated.

### Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical
Vedolizumab

policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:

For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical